Varenicline Augmentation of Patch Outcomes in Heavy Drinkers' Smoking Cessation

PHASE4CompletedINTERVENTIONAL
Enrollment

122

Participants

Timeline

Start Date

March 29, 2018

Primary Completion Date

September 30, 2020

Study Completion Date

October 15, 2020

Conditions
Smoking CessationAlcohol Drinking
Interventions
DRUG

Chantix

Chantix given alongside standard smoking cessation treatment, and administered per manufacturer's instructions \[0.5 mg once per day for Days 1 to 3, 0.5 mg twice per day for Days 4 to 7, then one 1.0 mg tablet twice per day\]

BEHAVIORAL

Behavioral Counseling Sessions

One-to-one behavioral counseling sessions with a trained therapist

DRUG

NicodermCQ

Nicotine patches provided over 12 week participation

DRUG

Placebo

Identical in appearance to varenicline \[0.5 mg once per day for Days 1 to 3, 0.5 mg twice per day for Days 4 to 7, then one 1.0 mg tablet twice per day\]

Trial Locations (1)

60637

Clinical Addictions Research Laboratory, Chicago

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

University of Chicago

OTHER

NCT02859142 - Varenicline Augmentation of Patch Outcomes in Heavy Drinkers' Smoking Cessation | Biotech Hunter | Biotech Hunter